Prognosis
Gilead Asked by House Democrats for Details on HIV Drug's Price
- Truvada's $2,000 monthly cost criticized by AIDS activists
- Letter comes month after CEO O'Day appeared before House panel
This article is for subscribers only.
House Democrats sent a letter to Gilead Sciences Inc. seeking documents on pricing and patents for its HIV drug Truvada, whose high cost has drawn the ire of lawmakers and AIDS activists.
The letter from the Committee on Oversight and Reform comes over a month after Gilead Chief Executive Officer Daniel O’Day went before the committee and defended the company’s roughly $2,000 monthly price tag for Truvada, which is used for pre-exposure prophylaxis, or PrEP. A generic version of the treatment can be bought for as little as $210 a month in other countries, the committee said.